A new instrument may provide physicians insight into satisfaction with acromegaly treatment.
The presence of a pituitary tumor on magnetic resonance imaging confirmed the diagnostic hypothesis.
The FDA has approved pasireotide (Signifor long-acting release) for treatment of acromegaly.
Researchers have discovered a single gene in a region of the X chromosome that may cause excessive growth in children.
The Endocrine Society has issued a clinical practice guideline for the diagnosis and treatment of acromegaly.
In patients with acromegaly, ATL1103 significantly reduced serum insulin-like growth factor I (IGF-1) after 14 weeks of treatment.
Thyroid nodular disease and thyroid cancer prevalence appears to be higher in patients with acromegaly.
Some cardiovascular risk factors and adiposity increased during acromegaly remission.
Novartis announced results from a phase 3 trial for Signifor LAR (pasireotide LAR; SOM230) in patients with acromegaly for whom current standard of care provides inadequate disease control.
Endocrinology Advisor Articles
- Imaging Studies in Hypothyroidism Evaluation Linked to Unnecessary Risks
- Once-Weekly Omarigliptin Improves Glycemic Control in Type 2 Diabetes
- Transoral Endoscopic Thyroidectomy Vestibular Approach: Safety and Outcomes
- Insulin Glargine Associated With Breast Cancer Risk in T2D
- High Grip Strength Associated With Lower Risk for Diabetes-Related AEs
- Update on Vitamin D and Calcium Supplements for Reducing Fracture Risk
- Bariatric Surgery: An Effective Treatment for Type 2 Diabetes
- Lower Risk for SGLT2i-Associated Genitourinary Infection With DPP-4i
- Severe Hypoglycemia Associated With Increased Mortality Risk in T2D
- Efficacy of CGM in Preterm Infants of Mothers With Diabetes
- Increased Risk of Diabetes, Post-Diabetes Pneumonia for Patients With COPD
- Pancreatic Exocrine Dysfunction Occurs After Islet Autoimmunity in T1D
- T2D in African American Women Ups ER-negative Breast Cancer Risk
- High-Sensitivity CRP and LDL-C Predictive of Subsequent MACE in T2D
- Risks Associated With Denosumab Discontinuation